Trials / Completed
CompletedNCT02151656
F17464 in Acute Schizophrenia Trial
Effects of F17464 in Acute Exacerbation of Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design: double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design, multicentre study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F17464 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-05-30
- Last updated
- 2016-12-16
Locations
27 sites across 5 countries: France, Hungary, Latvia, Romania, Russia
Source: ClinicalTrials.gov record NCT02151656. Inclusion in this directory is not an endorsement.